Psilocybin Therapy—A Breakthrough Alternative to SSRIs for Depression

Tyler Kjorvestad, MD

The study *Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Psilocybin Therapy for Depression* [1], published in the *American Journal of Psychiatry*, offers a compelling comparison of psilocybin therapy and escitalopram, a selective serotonin reuptake inhibitor (SSRI), in treating major depressive disorder (MDD). Using functional MRI (fMRI) to measure blood-oxygen-level-dependent (BOLD) signals, this randomized controlled trial highlights divergent effects on emotional processing. The findings reveal significant drawbacks of SSRIs, particularly their side effects, while showcasing psilocybin's potential as a transformative treatment. When paired with insights from *A Critical Evaluation of QIDS-SR-16 Using Data from a Trial of Psilocybin Therapy Versus Escitalopram Treatment for Depression* [2], psilocybin emerges as a superior option, offering fewer side effects and a streamlined dosing schedule.

Decoding BOLD Imaging for Everyone

BOLD imaging, used in fMRI scans, is like a window into brain activity. Picture your brain as a network of regions that "light up" when you experience emotions or thoughts. When a region, such as the amygdala (linked to fear responses), is active, it demands more oxygen-rich blood. BOLD imaging tracks these blood flow changes, creating a visual map of which brain areas are working hardest. In this study, BOLD signals showed how emotional face stimuli (happy, fearful, neutral) activated brain regions before and after treatment, revealing how escitalopram and psilocybin reshape emotional responses.

Major Findings: Escitalopram vs. Psilocybin

The trial compared two MDD groups: one received two 25-mg psilocybin doses (with placebo capsules) three weeks apart, while the other took daily escitalopram (10–20 mg) for six weeks plus two 1-mg psilocybin doses (a non-active placebo). Both groups had equal psychological support. The results highlighted critical differences:

- **Escitalopram Reduced Emotional Responsiveness**: After six weeks, the escitalopram group displayed significantly lower BOLD responses to emotional faces (fearful, happy, neutral) in regions like the dorsolateral prefrontal cortex and insula. The amygdala, vital for fear processing, showed reduced activity, especially for fearful faces, consistent with *emotional blunting*—a common SSRI side effect impacting about half of users [3]. Patients scored lower on the Laukes Emotional Intensity Scale (LEIS), reflecting a dulled emotional experience. Escitalopram also increased sexual dysfunction, as shown by elevated Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ) scores, a frequent SSRI issue affecting libido and sexual performance [4]. Notably, the reduced amygdala activity may explain why SSRIs are often more effective for anxiety disorders than depression. Anxiety conditions, like generalized anxiety disorder, are linked to heightened amygdala reactivity to threat stimuli. By dampening this response, SSRIs can reduce excessive fear and worry, providing targeted relief for anxiety symptoms [5]. However, this same

blunting may hinder emotional engagement in depression, where reconnecting with emotions is therapeutic.

- **Psilocybin Maintained Emotional Vitality**: Conversely, the psilocybin group showed little change in BOLD responses, with a slight uptick for neutral faces. Amygdala activity remained stable, indicating that psilocybin preserves emotional processing. Higher LEIS scores suggested increased emotional intensity, and lower PRSexDQ scores indicated minimal sexual dysfunction. Despite significant reductions in depressive symptoms (assessed via the Quick Inventory of Depressive Symptomatology, QIDS-SR-16), psilocybin achieved these results with only two doses, contrasting with escitalopram's daily intake.

These outcomes suggest distinct neural pathways. SSRIs increase serotonin through reuptake inhibition, potentially over-activating inhibitory 5-HT1A receptors in limbic areas, causing emotional and sexual side effects [6]. Psilocybin, acting as a 5-HT2A receptor agonist, enhances cortical plasticity and emotional reconnection, avoiding these drawbacks [7].

QIDS-SR-16 Analysis Bolsters Psilocybin's Case

Weiss et al. [2] critique the QIDS-SR-16, used in the original trial [8] revealing its limitations in capturing psilocybin's benefits. The QIDS-SR-16's compound items (e.g., merging insomnia and hypersomnia) and sum-scoring obscure improvements in specific symptoms. The analysis showed psilocybin outperformed escitalopram in areas like energy, libido, and anhedonia—key to quality of life but underemphasized in QIDS-SR-16. Psilocybin excelled in reducing *depressed mood* and *anhedonia*, among the most debilitating depression facets [9], suggesting its advantages may be undervalued by broad scales like QIDS-SR-16.

Study Critiques and Limitations

The study, while robust, has caveats. The design was slightly asymmetrical: the escitalopram group received 1-mg psilocybin doses, while the psilocybin group had no escitalopram exposure, though 1-mg psilocybin lacks psychoactive effects [10]. Posttreatment fMRI scans, conducted hours after the last escitalopram dose but three weeks after psilocybin, may have missed psilocybin's acute neural impacts, as prior research noted increased amygdala activity one day post-dose [11]. The passive-viewing fMRI task may have been less sensitive than active paradigms. Functional unblinding, where psilocybin's psychoactive effects may reveal treatment allocation, is a concern, though expectancy did not significantly influence outcomes [12]. The small sample (21 escitalopram, 25 psilocybin) and COVID-19-related dropouts call for larger trials.

Why Psilocybin Outshines SSRIs

Psilocybin and classical psychedelics offer substantial advantages over SSRIs for MDD. Unlike SSRIs, which require daily dosing for 4–8 weeks with moderate efficacy [13], psilocybin delivers powerful antidepressant effects with just 2–3 doses weeks apart, easing patient burden and boosting compliance. Its rapid action, often within days [14], contrasts with SSRIs' delayed onset. Critically, psilocybin avoids SSRIs' burdensome side effects. Emotional blunting, which can impede emotional recovery, is absent; instead, psilocybin fosters emotional engagement [15]. Sexual dysfunction, a leading cause of SSRI discontinuation [4], is significantly reduced, as PRSexDQ data confirm.

Psilocybin's 5-HT2A receptor-driven neuroplasticity creates a window for

psychological growth, amplified by therapy [7], unlike SSRIs' reliance on chronic serotonin modulation, which often sacrifices emotional and sexual health. Weiss et al. [2] highlight psilocybin's edge in tackling core symptoms like anhedonia, offering a more comprehensive recovery.

Conclusion

Wall et al. [1], supported by Weiss et al. [2], signal a paradigm shift in depression care. Psilocybin therapy, with its minimal dosing, preserved emotional and sexual function, and potent antidepressant effects, surpasses SSRIs. While larger studies are needed to refine protocols, psilocybin's promise is undeniable, offering a future where depression treatment is both effective and life-enhancing.

AUTHOR INFORMATION

Tyler Kjorvestad, M.D.
(tkjorvestad@kumc.edu)

Kjorvestad, T. (2025, June). Psilocybin Therapy- A breakthrough Alternative to SSRIs for Depression. *The Journal of Psychedelic Psychiatry*, *7*(2).

REFERENCES:

1. Wall, M. B., Demetriou, L., Giribaldi, B., Roseman, L., Ertl, N., Erritzoe, D., Nutt, D. J., & Carhart-Harris, R. L. (2025). Reduced brain responsiveness to emotional stimuli with escitalopram but not psilocybin therapy for depression. *American Journal of Psychiatry*, 182(6), 569–582. https://doi.org/10.1176/appi.ajp.20230751
2. Weiss, B., Erritzoe, D., Giribaldi, B., Nutt, D. J., & Carhart-Harris, R. L. (2023). A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depression. *Journal of Psychopharmacology*, 37(7), 717–732. https://doi.org/10.1177/02698811231167848
3. Goodwin, G. M., Price, J., De Bodinat, C., & Laredo, J. (2017). Emotional blunting with antidepressant treatments: A survey among depressed patients. *Journal of Affective Disorders*, 221, 31–35. https://doi.org/10.1016/j.jad.2017.05.048
4. Cascade, E., Kalali, A. H., & Kennedy, S. H. (2009). Real-world data on SSRI antidepressant side effects. *Psychiatry (Edgmont)*, 6(2), 16–18.
5. Sheline, Y. I., et al. (2001). Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: An fMRI study. *Biological Psychiatry*, 50(9), 651–658.
6. Carhart-Harris, R. L., & Nutt, D. J. (2017). Serotonin and brain function: A tale of two receptors. *Journal of Psychopharmacology*, 31(9), 1091–1120. https://doi.org/10.1177/0269881117725915
7. Carhart-Harris, R. L., Chandaria, S., Erritzoe, D. E., Gazzaley, A., Girn, M., Kettner, H., Mediano, P. A. M., Nutt, D. J., Rosas, F. E., Roseman, L., Timmermann, C., Weiss, B., & Zeifman, R. J. (2023). Canalization and plasticity in psychopathology. *Neuropharmacology*, 226, Article 109398. https://doi.org/10.1016/j.neuropharm.2022.109398
8. Carhart-Harris, R. L., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of psilocybin versus escitalopram for depression. *New England Journal of Medicine*, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994

9. Fried, E. I., Nesse, R. M., Zivin, K., Guille, C., & Sen, S. (2016a). Depression is more than the sum score of its parts: Individual symptom profiles and their association with functional impairment. *Psychological Medicine*, 46(16), 3359–3369. https://doi.org/10.1017/S0033291716001498
10. Madsen, M. K., Fisher, P. M., Burmester, D., Dyssegaard, A., Stenbæk, D. S., Kristiansen, S., Johansen, S. S., Lehel, S., Linnet, K., Svarer, C., Erritzoe, D., Ozenne, B., & Knudsen, G. M. (2019). Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. *Neuropsychopharmacology*, 44(7), 1328–1334. https://doi.org/10.1038/s41386-019-0324-9
11. Carhart-Harris, R. L., Roseman, L., Bolstridge, M., Demetriou, L., Pannekoek, J. N., Wall, M. B., Tanner, M., Kaelen, M., McGonigle, J., Murphy, K., Leech, R., Curran, H. V., & Nutt, D. J. (2017). Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. *Scientific Reports*, 7(1), Article 13187. https://doi.org/10.1038/s41598-017-13282-7
12. Szigeti, B., Nutt, D., Carhart-Harris, R., & Erritzoe, D. (2022). On the fallibility of placebo control and how to address it: A case study in psychedelic microdosing. *PsyArXiv*. https://doi.org/10.31234/osf.io/7q4cs
13. Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., Egger, M., Takeshima, N., Hayasaka, Y., Imai, H., Shinohara, K., Tajika, A., Ioannidis, J. P. A., & Geddes, J. R. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. *The Lancet*, 391(10128), 1357–1366. https://doi.org/10.1016/S0140-6736(17)32802-7
14. Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., Taylor, D., Pilling, S., Curran, V. H., & Nutt, D. J. (2016). Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. *The Lancet Psychiatry*, 3(7), 619–627. https://doi.org/10.1016/S2215-0366(16)30065-7

Roseman, L., Haijen, E., Idialu-Ikato, K., Kaelen, M., Watts, R., & Carhart-Harris, R. (2019). Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory. *Journal of Psychopharmacology*, 33(9), 1076–1087. https://doi.org/10.1177/0269881119855974